But despite their widespread use (around 2.5 million Canadians have osteoarthritis) these medications are also known to cause severe, sometimes life-threatening adverse effects within the body, particularly in the gastrointestinal tract.
A novel anti-inflammatory drug being developed and commercialized by an inflammation expert at McMaster University has shown promise in relieving symptoms of inflammation, while substantially reducing the incidence of bleeding and intestinal damage often caused by NSAIDs.
The research is published in the March issue of the British Journal of Pharmacology.
John Wallace, a pharmacologist and director of the Farncombe Family Digestive Health Research Institute at McMaster University, compared naproxen, a commonly used NSAID, to a novel anti-inflammatory drug, ATB-346, which he developed in collaboration with a team of Italian chemists and is now commercializing through his company, Antibe Therapeutics Inc.
ATB-346 is a derivative of naproxen which releases hydrogen sulfide. Evidence from animal studies suggests that in small quantities, hydrogen sulfide can protect the stomach from injury and can accelerate the healing of pre-existing ulcers.
"I've been working on NSAIDs for over 20 years," said Wallace, a professor of medicine in the Michael G. DeGroote School of Medicine at McMaster University. "This particular drug is, by far, the shining star. We've tested it in every model where it should fail, and it has performed exceptionally well."
To examine the gastrointestinal safety and anti-inflammatory effectiveness of ATB-346, Wallace and his co-investigators tested the drug in healthy rats as well as those with arthritis and inflammation. The researchers also examined the impact of the drug on rats with compromised gastrointestinal tracts, a model which mimicked the clinical scenario in which NSAIDs are frequently used and have caused damage such as bleeding and ulcers.
"From the beginning, we decided that we were going to do the most rigorous testing of any NSAID that's ever been done," Wallace said. "We very deliberately tested the drug in models where NSAIDs fail."
The researchers found that ATB-346 was at least as effective as naproxen in relieving inflammation in animal models. They also discovered that ATB-346 was in the order of 100 times safer than naproxen, causing little or no damage to the stomach and small intestine.
When given to rats with impaired gastrointestinal tracts, ATB-346 did not cause any gastric damage. Moreover, the researchers observed that it enhanced, rather than inhibited, healing of pre-existing ulcers.
Finally, unlike naproxen, ATB-346 had no effect on blood pressure in rats with hypertension, suggesting the drug may have less cardiovascular risks than conventional NSAIDs.
The researchers concluded that H2S-releasing NSAIDs appear to represent a promising alternative to existing therapies for the treatment of inflammation and pain. Future research will focus on the potential cardiovascular benefits of these drugs.
Antibe Therapeutics was founded by Wallace in 2004. The company specializes in developing hydrogen sulfide-releasing drugs to treat inflammatory disorders.
About McMaster University
McMaster University, one of four Canadian universities listed among the Top 100 universities in the world, is renowned for its innovation in both learning and discovery. It has a student population of 23,000, and more than 140,000 alumni in 128 countries.
For more information, please contact:Veronica McGuire
Veronica McGuire | EurekAlert!
Not of Divided Mind
19.01.2017 | Hertie-Institut für klinische Hirnforschung (HIH)
CRISPR meets single-cell sequencing in new screening method
19.01.2017 | CeMM Forschungszentrum für Molekulare Medizin der Österreichischen Akademie der Wissenschaften
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
19.01.2017 | Earth Sciences
19.01.2017 | Life Sciences
19.01.2017 | Physics and Astronomy